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Abstract
Tissue transglutaminase (tTG) plays an important role in celiac disease pathogenesis and antibodies to tTG are a diagnostic marker of gluten­
sensitive enteropathy. The aim of this study was to investigate the localization of tTG in the duodenal mucosa in control tissues and in differ­
ent histological stages of celiac disease by using a commercial and a novel set of ant¡-tTG monoclonal antibodies, to see whether this assess­
ment can be useful for diagnostic purpose. The distribution of tTG was firstly evaluated in 18 untreated celiac patients by using a commer­
cial monoclonal antibody (CUB7402) against tissue transglutaminase enzyme and directed against the loop-core region of the enzyme. 
Thereafter, in further 30 untreated celiac patients we employed three newly characterized anti-tTG monoclonal antibodies produced against 
recombinant human-tTG. The epitopes recognized are located in three distinct domains of the protein corresponding to the core, C1 and C2 
protein structure. Eleven age- and sex-matched patients with chronic duodenitis acted as controls. All subjects underwent upper endoscopy 
to obtain biopsy samples from the duodenum. Overall, we found that (/') tTG is equally expressed in CD at different stages of disease; (/'/') tTG 
is expressed, at similar level, in CD and controls with duodenitis. Assessment of tTG level in biopsy samples by immunohistochemical 
methods is not useful in the clinical diagnostic work-up of CD.
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Introduction
Celiac disease (CD) is a gluten-dependent enteropathy that develops 
in genetically susceptible individuals, with a prevalence of 1% in 
the general population [1], CD is a unique autoimmune disease in 
which all the factors involved in the autoimmune cascade 
can be recognized: endogenous risk factors (the HLA-DQ het­
erodimers A1 ‘0501 ,B1 ‘0201 (DQ2), A1 ‘0301 ,B 1 ‘0302 (DQ8)); a 
trigger (the gluten); an autoantigen (type 2 tissue transglutami­
nase [tTG]); auto-antibodies (anti-tissue tTG antibodies) [2],
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Gluten peptides activated intestinal HLA-DQ2 restricted T cells 
from CD patients, leading to the release of inflammatory cytokines 
and T-cell-mediated inflammatory response, have been implicated 
in the development of intestinal lesions of CD.
Two findings have shed light onto the interaction between the 
trigger, the auto-antigen and the HLA DQ2. Several gluten pep­
tides are glutamyl donor substrate for the tTG, resulting in the 
formation of deamidated glutamine residues into negatively 
charged glutamic acid. The gliadin peptides deamidated by tTG 
bind with higher affinity to HLA DQ2 or DQ8 than their non­
deamidated counterparts and can elicit a stronger proliferative 
response of gliadin-specific CD4+ T-cell clones [3, 4], Moreover, 
the tTG catalyses the binding of gliadin peptides to intestinal 
extracellular matrix proteins, thus demonstrating the role of tTG
do i : 10.1111/j.1582-4934.2008.00325.X
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in creating immunogenic neoepitopes and enhancing antigenic 
presentation of gliadins [5],
Another inflammatory role of the tTG depends from its ability 
to mediate T-cell migration across cytokine-activated endothelium 
into inflamed tissues [6], Thus, in the development of mucosal 
atrophy of CD, the tTG is overexpressed, particularly within the 
basement membrane and the lamina propria, with increased ente- 
rocyte expression compared to the controls displaying normal 
mucosa [7],
The expression of tTG within specific areas suggests that the 
enzyme could be translocated from the intracellular to the pericel­
lular environment in the lamina propria by some not yet identified 
cells. Moreover, the tTG deposits along the lamina propria and 
around the mucosal vessels represent a specific target of the IgA 
anti-tTG antibodies in revealing early developing CD among symp­
tomatic and asymptomatic patients genetically predisposed to 
gluten intolerance [8, 9], Furthermore, it has been recently reported 
that anti-tTG assay of the culture medium of biopsy specimens can 
improve the accuracy of CD diagnosis in patients negative for 
serum antibodies [10],
Despite the interest in the biological properties of the tTG in the 
pathogenesis of CD, the distribution of this enzyme has been to 
date only studied by using one monoclonal antibody (CUB7402) 
developed against guinea-pig type tissue tTG enzyme and directed 
mainly against the loop-core region of the enzyme [11-13],
The aim of the present study was to investigate the localization 
of tTG within the duodenal mucosa in controls and in different his­
tological stages of CD and to identify the cells involved in the syn­
thesis of tTG by using a new set of three anti-tTG monoclonal anti­
bodies. These monoclonal antibodies were produced against 
recombinant human tTG and their epitopes were shown to be 
located in three distinct domains of the protein corresponding to 
the core, C1 and C2 protein structure [14],
Materials and methods
Study groups
For the first step, based on the commercial antibody CUB7402 (see 
below), 18 untreated CD patients, 9 males and 9 females, age range 
15-76 years old, were recruited. These patients were subdivided in: M-0 
type 1 infiltrative lesions (3 patients); M-0 type 2 hyperplastic lesions (6 
patients); M-0 type 3 destructive lesions (9 patients). The latter patients 
were classified as: M-0 3C (5 patients), M-0 3B (3 patients), and M-0 3A 
(1 patient). The clinical suspicion of CD was supported by a positive test 
for indirect immunofluorescence on sections of monkey esophageal 
smooth muscle (anti-endomysial antibodies [EMA] IgA) and/or enzyme- 
linked immunosorbent assay with guinea pig tTG or dot blot test with 
human recombinant tTG (tTG IgA).
For the second step based on the three new anti-tTG monoclonal 
antibodies (see below) 30 untreated CD patients, 18 males and 12 
females, age range 1-75 years old, were recruited. These patients were 
classified as: M-0 type 1 infiltrative lesions (5 patients); M-0 type 2 
hyperplastic lesions (9 patients); M-0 type 3 destructive lesions 
(16 patients). The latter patients were classified as M-0 3A (5 patients), 
M-0 3B (6 patients) and M-0 3C (5 patients).
As control group, 11 age- and sex-matched patients with chronic duo­
denitis, all negative for serological tests and undergoing endoscopy for 
chronic aspecific upper gut symptoms were recruited and tested with the 
immunohistochemical methods described below.
Monoclonal antibody production and purification
Production and characterization of three different anti-tTG monoclonal 
antibodies was described elsewhere [14], We identified the epitopes rec­
ognized by MAB 1 alpha-TG2, MAB 2 alpha-TG2, MAB 3 alpha-TG2 
antibodies as located in the core, C1 and C2 regions of the enzyme, 
respectively. Ascitic fluid was prepared in BALB/c mice by inoculating 
them with the hybridoma cells. Then 100-300 p.l of ascites were diluted 
to 1 ml with ddH2O, and the pH of the crude antibody preparation adjusted 
by adding 1/10 volume of 1.0 M Tris pH 8.0. The antibody solution was 
passed through a pre-washed protein G bead column, and the beads were 
washed with 10 column volumes of 100 mM Tris pH 8.0 and 10 column 
volumes of 10 mM Tris pH 8.0. The column was then eluted with 50 mM 
glycine pH 3.0. The eluate was collected in tubes containing 1/10 volume 
of 1M Tris pH 8.0, and immediately each tube was mixed gently to bring 
the pH back to neutral. Protein concentration was measured using the 
Bradford reagent (Sigma, Sigma-Aldrich, St Louis, MO, USA).
Immunohistochemistry
Duodenal sampling was carried out after a standard endoscopic procedure, 
by obtaining at least four samples from different portions of the duodenum, 
two in the proximal duodenum and two in the distal duodenum, so that 
some samples could be frozen. Biopsy specimens, correctly oriented on 
millipore filters, were embedded in paraffin, then 5-p.m thick sections were 
obtained and stained with haematoxylin and eosin. Immunohistochemistry 
was performed according to a standard technique. In the first step was used 
the monoclonal CUB7402 (MS-224-P, Neo Markers, Fremont, CA, USA) at 
dilution 1:1000. In the second step, we employed three new anti-tTG mon­
oclonal antibodies (MAB 1 alpha-TG2, dilution 1:2000; MAB 2 alpha-ETG, 
dilution 1:4000; MAB 3 alpha-ETG dilution 1:6000). Anti-CD3 monoclonal 
antibody (Dako, Glostrup, Denmark) was used to better identify intra­
epithelial lymphocytes (IEL). To test the hypothesis that tTG was produced 
by endothelial cells, we also used anti-CD31 and anti-CD34 monoclonal 
antibodies against the vascular and endothelial structures (Dako) and anti­
bodies against IgA (Dako).
Data analysis
All slides were coded and analysed in blind by two pathologists (W and 
AG). Duodenal histological lesions were classified according to the revised 
criteria proposed by the United European Gastroenterology [15], 
According to recent criteria, the upper normal limit for IEL has been estab­
lished as 25 IEL/100 epithelial cells [16], thus we adopted this cut-off. A 
mucosa with a villous/crypt ratio of 3:1 (plus a normal IEL count) was con­
sidered as normal, whereas a decrease of the villous/crypt ratio led to the 
following definition of atrophy: 2:1 ratio = mild atrophy; 1:1 ratio = moder­
ate atrophy; no villi (flat mucosa) = total atrophy.
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Fig. 1 The arrows show positivity for 
tTG under the superficial epithelium 
of villi with CUB 7402 in a case of ini­
tial lesion (A) and total atrophy (B) 
(paraffin fixed biopsy, original magni­
fication -100). (C) (original magnifi­
cation - 40) and (D) (original magni­
fication - 20) show frozen biopsies.
Results
Localization of tTG within the mucosal duodenal 
sections with CUB4702
This antibody targets the Core-loop region of the tTG. In the first 
group of 18 CD patients, a strong staining was shown in epithelial 
cells and in the lamina propria of the villi under the superficial 
epithelium; the positivity was similar in frozen and fixed material 
(Fig. 1). No significant differences in the localization of staining 
were observed with respect to the grade and severity of villous 
atrophy. In the control group (11 cases), the distribution of the 
staining was the same as in CD patients (Fig. 2).
Localization of tTG within the mucosal duodenal 
sections with the three new mAbs
The recently characterized mAbs directed to human tTG display all 
the determined epitopes corresponding to structural loops 
exposed on the surface of the protein [14], These different recog­
nition patterns account for the differences between the antibodies 
and, from a practical point of view, may be useful for experimen­
tal purposes. Thus, we analysed a second set of 30 CD cases with 
these three different mAbs. As it can be seen in Figure 3, positiv­
ity was seen on epithelial cells, more evident for Mab 1 and Mab 
3, and under the superficial epithelium in the axis of villi. As for the 
first set of samples positivity was similar for frozen and fixed 
material. Interestingly, mAb3 resulted also positive in Paneth cells 
(Fig. 4). Again, no discernible differences were observed with 
respect to the grade and severity of villous atrophy.
A positive labelling (although of lesser intensity) was also 
observed in controls. CD31 and CD34 were positive in endothelial 
cells and vascular channels, with the same localization observed 
for tTG with CUB 7402 and the three Mabs (Fig. 5). The staining 
observed for IgA was evident in plasma cells of the basal part of 
lamina propria (Fig. 6), but not in the lamina propria under the 
superficial epithelium.
Discussion
To date, there are few doubts that tTG is an important component 
of CD, for both its pathogenesis and diagnosis [17,18], The iden­
tification of tTG as the anti-endomysial autoantigen in this condi­
tion [19] allowed standardized tests to be introduced in clinical 
practice that proved tTG to be a reliable marker for CD [20, 21 ]. In 
fact, anti-tTG antibodies display high sensitivity (93%) and speci­
ficity (98%) for the diagnosis of CD, when villous atrophy is pres­
ent [22], and values 10 times higher than the cut-off are almost 
always associated with diagnostic pathological findings [23, 24],
These antibodies are produced in the intestinal mucosa [25] 
and are deposited along the villous and crypt basement mem­
branes in the mucosa from patients with CD before they can be 
detected in the circulation and before the mucosal damage is pres­
ent [26], Recent evidence in man also suggests that tTG autoanti­
bodies per se may play an important role in the progression and 
maintenance of the trophic mucosal lesion in CD by interacting 
with extracellular membrane-bound tTG [27],
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Fig. 2 The arrows show positivity for 
tTG under the superficial epithelium of 
villi with CUB 7402 on paraffin fixed 
(A, original magnification - 20) and 
frozen biopsy (B, original magnifica­
tion -100).
Fig. 3 The arrows show the staining patterns of the three new mAbs in paraffin fixed sections. The figures above show initial lesions, the figures below 
show atrophic lesions. (A) and (D) mAb 1, (B) and (E) mAb 2, (C) and (F) mAb 3 (original magnification -100).
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Fig. 4 The arrows show positivity for the Paneth cells with mAh 3 
(paraffin fixed biopsies, original magnification A <40, B <100).
We investigated whether the tTG expression by immunohisto­
chemical methods might be useful in the evaluation of CD, since 
ultrastructural and enzymatic studies showed an increase of tTG in 
CD compared to controls [28], To this purpose, we used the com­
mercial mAb (CUB4702) and a new set of three mAbs recently char­
acterized by our group. We decided to use multiple probes as in pre­
liminary results we were able to show that these four monoclonal 
antibodies provide different staining patterns on histological sec­
tions of human umbilical cord. The most likely explanation of this 
finding is that tTG, the structure of which is highly sensitive to acti­
vation by Ca2+ and GTP [29, 30], may assume different functional 
conformations, thus exposing the epitopes differently in different 
histological compartments. This interpretation may be of practical 
relevance, implying that the use of multiple mAbs to tTG, that map 
different enzyme conformation, could be used for a full characteri­
zation of the localization and quantification of enzyme deposits.
The chronic tTG enzyme expression (more than the enzyme 
quantity) at epithelial sites promotes the formation of high molec­
ular weight complexes containing tTG-gliadin-mucosal proteins 
cross links, which in turn creates long-term reservoirs of potential 
autoantigens for the development of gluten-dependent autoim­
mune disorders in CD [5], The endothelial over-expression of the 
tTG, observed in the present study, confirms the role of the tTG in 
the course of tissue inflammation. In fact, the tTG on cytokine- 
activated endothelium actively operates in mediating the recruit­
ment of CD8+ T cells migration across the inflamed endothelium 
and the infiltration of tissue inflammation [31],
We demonstrated that the tTG enzyme is expressed in the cyto­
plasm of Paneth cells; there is considerable interest in a possible 
link between the presence of the tTG in these cells and the devel­
opment of the gluten-dependent inflammation. It may be that active
Fig. 5 Expression of CD31 (A) and 
mAb 3 (B) on consecutive sections 
(original magnification <20).
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Fig. 6 The arrows show positivity for IgA in plasma cells of the basal 
part of lamina propria (original magnification A <20, B : ■ 40).
antigens which are both self-epitopes and gliadin epitopes, lead­
ing to the production of anti-tTG antibodies [33, 34], The anti-tTG 
antibodies are synthesized only at the intestinal site [25], and the 
anti-tTG serum concentration is related to the degree of the intes­
tinal lesion [35], Furthermore, in the contest of genetically gluten­
intolerance and in the absence of morphological or serological 
signs of CD, patients show gluten-dependent anti-tTG intestinal 
deposits before the development of the villous atrophy [8, 9], This 
means that in the early stage of CD the development of trangluta- 
minase-dependent immunocomplexes represent specific indica­
tors of the disease and they might be considered a future, reliable 
marker for the CD diagnosis without villous atrophy.
The overall results showed that: (/') tTG is equally expressed 
in CD at different stages of disease; (/'/) tTG is expressed, almost 
with the same intensity, in CD, and controls. Our results were at 
variance with those reported by Sakly and colleagues [13] that 
found increased tTG expression in CD, but substantially agreed 
with another study showing that immunohistochemical assess­
ment of tTG is not suitable for diagnosis of CD [36], Moreover, 
we were not able to confirm with immunohistochemical methods 
the findings of Korponay-Szabo and colleagues of IgA positivity 
in the lamina propria under the superficial epithelium. On the 
other hand, our results suggest that tTG might be produced 
by endothelial cells, as hypothesized in animal studies [37],
In conclusion, the assessment of tTG by immunohistochemical 
methods is not useful in the clinical diagnostic work-up of CD, 
whereas the detection of anti-tTG levels in patients' sera repre­
sents an important tool for both diagnostic and follow-up pur­
poses [38, 39],
deamidation of gluten derived peptides by the Paneth's tTG enzyme 
leads to up-regulation of inflammatory immune response [32],
It has been hypothesized that tTG crosslinks itself to gluten to 
make macromolecular complexes causing the formation of new
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